Abstract
Abstract Non-small cell lung cancer (NSCLC), encompassing adenocarcinomas, squamous cell carcinomas, and large cell carcinomas, is a prevalent and varied lung cancer type. It holds a significant share of lung malignancies in India and the United States. The advancement of local NSCLC is significantly influenced by smoking, and the recommended therapeutic approach for these cases is chemoradiotherapy. However, the prognosis remains challenging, necessitating innovative treatments. Durvalumab, an immune checkpoint inhibitor, shows promise against unresectable stage 3 NSCLC. Blocking programmed death ligand-1 interactions amplify immune responses against tumors. Durvalumab has exhibited efficacy in trials and improved survival when combined with chemotherapy for extensive-stage small-cell lung cancer. Adverse effects include cough, rash, hypothyroidism, and abdominal pain. Immunotherapies like durvalumab bring hope for better outcomes, but continuous research is crucial for refining treatments and enhancing patient survival.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
